Fibrinolytics, enzyme inhibitors, and cancer survival

M Schmitt; V Magdolen; K Mengele; U Reuning; J Foekens; EP Diamandis; N Harbeck

doi:10.4081/hmr.v1i9.320

Abstracts

3 June 2009

Vol. 1 No. 9 (2005)

https://doi.org/10.4081/hmr.v1i9.320

Fibrinolytics, enzyme inhibitors, and cancer survival

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

185

Views

680

Downloads

Authors

M Schmitt

support@pagepress.org

V Magdolen

K Mengele

U Reuning

J Foekens

EP Diamandis

N Harbeck

The majority of cancer patients do not die from their primary tumor but from disseminated tumor cells traversing through the body to form distant metastases.1,2 As one of the initial steps in this process, tumors secrete the vascular permeability factor VEGF that prompts the neighboring microvasculature to become permeable to fibrinogen and to other plasma proteins.3,4 Extravasated plasma-derived fibrinogen is rapidly cleaved by the serine protease thrombin to generate cross-linked fibrin, a process which also constitutes the final step in the intravascular blood coagulation cascade.5-8